Capital Senior Living Corporation (CSU)

Constellation Software Inc. - Special Call Company Participants Jamal Baksh - CFO & Director Mark Miller - President & COO Conference Call Participants Richard Tse - National Bank Financial, Inc., Research Division Thanos Moschopoulos - BMO Capital Markets Equity Research David Kwan - TD Cowen, Research Division Samad Samana - Jefferies LLC, Research Division Paul Treiber - RBC Capital Markets, Research Division Kevin McVeigh - UBS Investment Bank, Research Division Presentation Operator Good afternoon, and welcome to the Constellation Software Inc. Conference Call and Webcast. [Operator Instructions] Please note this event is being recorded.

Rhapsido helps to inhibit release of histamine and proinflammatory mediators by targeting BTK, offering unique approach to CSU treatment 1 Well-controlled disease observed as fast as two weeks, with demonstrated safety profile that requires no lab monitoring 1 1.7 million people in US live with CSU; more than half remain symptomatic despite increasing doses of antihistamines 2,3 Remibrutinib also in clinical development for chronic inducible urticaria, food allergy, and hidradenitis suppurativa, expanding Novartis Immunology portfolio EAST HANOVER, N.J. , Sept. 30, 2025 /PRNewswire/ -- Novartis announced today that Rhapsido® (remibrutinib) received US Food and Drug Administration (FDA) approval as an oral treatment for adult patients with chronic spontaneous urticaria (CSU) who remain symptomatic despite H1 antihistamine treatment.

Ad hoc announcement pursuant to Art. 53 LR Rhapsido helps to inhibit release of histamine and proinflammatory mediators by targeting BTK, offering unique approach to CSU treatment 1 Well-controlled disease observed as fast as two weeks, with demonstrated safety profile that requires no lab monitoring 1   1.7 million people in US live with CSU; more than half remain symptomatic despite increasing doses of antihistamines 2,3 Remibrutinib also in clinical development for chronic inducible urticaria, food allergy, and hidradenitis suppurativa, expanding Novartis Immunology portfolio Basel, September 30,  2025 – Novartis announced today that Rhapsido® (remibrutinib) received US Food and Drug Administration (FDA) approval as an oral treatment for adult patients with chronic spontaneous urticaria (CSU) who remain symptomatic despite H1 antihistamine treatment.

TORONTO, Sept. 26, 2025 (GLOBE NEWSWIRE) -- Constellation Software Inc. (TSX:CSU) (“Constellation” or “CSI”) announced today its President, Mark Miller, and its Chief Financial Officer, Jamal Baksh, will host a live shareholder question and answer audio webcast on October 1st, 2025 at 2:30 p.m. ET to discuss the transition of Constellation's leadership from Mark Leonard to Mark Miller.

Constellation Software Inc. - Special Call Company Participants Mark Leonard - Founder, President & Director Paul McFeeters Conference Call Participants Thanos Moschopoulos - BMO Capital Markets Equity Research Stephanie Price - CIBC Capital Markets, Research Division Paul Treiber - RBC Capital Markets, Research Division David Kwan - TD Cowen, Research Division Samad Samana - Jefferies LLC, Research Division Presentation Operator Good day, and welcome to the Constellation Software Inc. Conference Call and Webcast. [Operator Instructions].

Recommendation for adults and adolescents based on Phase 3 trials showing Dupixent significantly reduced itch and hives at 24 weeks compared to placebo

Rapid and sustained efficacy regardless of baseline IgE levels in patients with CSU Rapid and sustained efficacy regardless of baseline IgE levels in patients with CSU

TORONTO, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Constellation Software Inc. (TSX:CSU) (“Constellation” or “CSI”) announced today it will host a live shareholder question and answer audio webcast on September 22, 2025 at 9:00 a.m. ET. regarding the impact of Artificial Intelligence technologies (“AI”) on software businesses.

TORONTO, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Constellation Software Inc. (TSX:CSU) (“Constellation” or the “Company”) today announced its financial results for the second quarter ended June 30, 2025 and declared a $1.00 per share dividend payable on October 10, 2025 to all common shareholders of record at close of business on September 19, 2025. This dividend has been designated as an eligible dividend for the purposes of the Income Tax Act (Canada). Please note that all dollar amounts referred to in this press release are in U.S. Dollars unless otherwise stated.

TORONTO, July 14, 2025 (GLOBE NEWSWIRE) -- Constellation Software Inc. (TSX:CSU) announced today it intends to release its second quarter results on August 8, 2025.

TORONTO, May 12, 2025 (GLOBE NEWSWIRE) -- Constellation Software Inc. (TSX:CSU) (“Constellation” or the “Company”) today announced its financial results for the first quarter ended March 31, 2025 and declared a $1.00 per share dividend payable on July 11, 2025 to all common shareholders of record at close of business on June 20, 2025. This dividend has been designated as an eligible dividend for the purposes of the Income Tax Act (Canada). Please note that all dollar amounts referred to in this press release are in U.S. Dollars unless otherwise stated.

Dupixent approved in the US as the first new targeted therapy in over a decade for chronic spontaneous urticaria Approval based on phase 3 studies demonstrating Dupixent significantly reduced itch and hives compared to placebo In the US, there are more than 300,000 adults and adolescents aged 12 years and older living with CSU who remain symptomatic despite antihistamine treatment CSU is the seventh disease with underlying type 2 inflammation in which Dupixent is approved Paris and Tarrytown, NY, April 18, 2025. The US Food and Drug Administration (FDA) has approved Dupixent (dupilumab) for the treatment of adults and adolescents aged 12 years and older with chronic spontaneous urticaria (CSU) who remain symptomatic despite histamine-1 (H1) antihistamine treatment.

Approval based on Phase 3 trials demonstrating Dupixent significantly reduced itch and hives compared to placebo In the U.S., there are more than 300,000 adults and adolescents aged 12 years and older living with CSU who remain symptomatic despite antihistamine treatment CSU is the seventh disease with underlying type 2 inflammation in which Dupixent is approved TARRYTOWN, N.Y. and PARIS, April 18, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has approved Dupixent® (dupilumab) for the treatment of adults and adolescents aged 12 years and older with chronic spontaneous urticaria (CSU) who remain symptomatic despite histamine-1 (H1) antihistamine treatment.

TORONTO, April 14, 2025 (GLOBE NEWSWIRE) -- Constellation Software Inc. (TSX:CSU) announced today it intends to release its first quarter results on May 12, 2025.

Constellation Software has delivered a 34% annualized return since its 2006 IPO, driven by its strategic acquisition of Vertical Market Software businesses. Founder Mark Leonard's long-term focus and decentralized model have enabled CSU to acquire over 800 mission-critical software businesses globally, ensuring minimal impact from economic cycles. Despite increased competition and acquisition costs, CSU's high ROIC and consistent revenue growth justify its valuation, making the recent 9% stock drop a buying opportunity.

- Greatly improved patient quality of life and reduced disease impact in patients with CSU and CIndU - - 82% of CSU patients reported that symptoms no longer had an impact on their quality of life at Week 52 - - 60% of CIndU patients reported that symptoms no longer had an impact on their quality of life at Week 12 -